ProstACT第3阶段的先进前列腺癌试验已开始其治疗阶段,第一批病人服了药,迄今没有任何安全问题。 The ProstACT Phase 3 trial for advanced prostate cancer has begun its treatment phase with the first patient dosed, showing no safety issues so far.

ProstACT全球第3阶段试验已经开始其随机扩大治疗阶段,第一位病人在先前结果的基础上进行了施药。 The ProstACT global Phase 3 trial has begun its randomized treatment expansion phase with the first patient dosed, building on prior results. 该试验评估了多个国家中晚期前列腺癌的试验性治疗方法,计划在未来几个月发布第一部分结果. The trial, evaluating an investigational treatment for advanced prostate cancer across multiple countries, plans to release Part 1 results in the coming months. 初步安全数据显示没有发生不利事件,审判正在按期进行,并完全遵守规章和道德规范。 Initial safety data show no adverse events, and the trial is progressing on schedule with full regulatory and ethical compliance. 结果将在公开公布前由独立委员会审查。 Results will be reviewed by an independent committee before public release.